Sun Pharmaceutical launches Winlevi cream in US market
1st Nov 2021

Sun Pharmaceutical Industries has launched Winlevi cream in US market. Winlevi cream used for the treatment of acne vulgaris in patients 12 years and older. A first-in-class topical androgen receptor inhibitor, Winlevi was approved by the US Food and Drug Administration (USFDA) in August 2020. Winlevi is the first FDA-approved acne drug with a first-in-class mechanism of action in nearly 40 years.

The US launch of Winlevi enhances Sun Pharma's specialty product portfolio and reflects commitment to meeting patients needs by providing innovative dermatology medicines.

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.